Survival Outcome of Salvage Therapy with Second-Generation Novel Agents in Patients with Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice

被引：0
|
作者：
Ozaki, Shuji [1 ]
Harada, Takeshi [2 ]
Udaka, Kengo [1 ]
Sekimoto, Etsuko [1 ]
Shibata, Hironobu [1 ]
Shigekiyo, Toshio [1 ]
Yagi, Hikaru [1 ]
Okamoto, Yasunobu [2 ]
Sogabe, Kimiko [2 ]
Oura, Masahiro [2 ]
Fujii, Shiro [2 ]
Nakamura, Shingen [2 ]
Miki, Hirokazu [3 ]
Kagawa, Kumiko [2 ]
Abe, Masahiro [2 ]
机构：
[1] Tokushima Prefectural Cent Hosp, Dept Hematol, Tokushima, Tokushima, Japan
[2] Tokushima Univ Hosp, Dept Hematol, Tokushima, Tokushima, Japan
[3] Tokushima Univ Hosp, Div Transfus Med & Cell Therapy, Tokushima, Tokushima, Japan
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-115818
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5577
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Outcome of older myeloma patients in relationship to comorbidities and availability of second-generation novel agents in a real-life setting
    d'Epinay, Murielle Lalive
    Guesewell, Sabine
    Graf, Nicole
    Mey, Ulrich J. M.
    Driessen, Christoph
    Hitz, Felicitas
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (04) : 716 - 723
  • [42] Daratumumab as salvage therapy in relapsed/refractory multiple myeloma patients after allogeneic stem cell transplantation
    Essmann, S.
    von Pein, U. -M.
    Klyuchnikov, E.
    Janson, D.
    Bonmann, S.
    Ayuk, F. A.
    Wolschke, C.
    Kroeger, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 190 - 190
  • [43] Daratumumab as salvage therapy in relapsed/Refractory multiple myeloma patients after allogenic stem cell transplantation
    Essmann, Sonja
    von Pein, Ute-Marie
    Klyuchnikov, Evgeny
    Janson, Dietlinde
    Bonmann, Stefan
    Ayuk, Francis Ayuketang
    Wolschke, Christine
    Kroeger, Nicolaus
    BONE MARROW TRANSPLANTATION, 2019, 54 : 496 - 496
  • [44] Duration of Treatment of Multiple Myeloma Regimens in Patients with Relapsed or Refractory Multiple Myeloma: Findings in US Clinical Practice Settings
    Potluri, Ravi
    Kanakamedala, Hemanth
    Chen, Clara
    Yasenchak, Christopher A.
    Ranjan, Sandip
    Papademetriou, Eros
    Bhandari, Hitesh
    Mann, Jasdeep
    Davis, Catherine
    BLOOD, 2017, 130
  • [45] Lovastatin as salvage immumomodulatory therapy in patients with refractory and relapsed multipla myeloma.
    Hus, M
    Grzasko, N
    Jawniak, D
    Szostek, M
    Dmoszynska, A
    BLOOD, 2005, 106 (11) : 449A - 450A
  • [46] CLINICAL EFFICACY OF VELCADE (BORTEZOMIB) AND DEXAMETHASONE THERAPY IN PATIENTS WITH REFRACTORY OR RELAPSED MULTIPLE MYELOMA
    Ionita, I.
    Cheveresan, M.
    Calamar, D.
    Ionita, C.
    Oros, D.
    Ionita, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 627 - 628
  • [47] Predictors of Second-Line Treatment Choice with Triplet Therapy in Routine Care Among Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Romanus, Dorothy
    Jhaveri, Mehul
    Labotka, Richard
    Henk, Henry
    Seal, Brian
    BLOOD, 2015, 126 (23)
  • [48] Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma.
    Mikhael, Joseph R.
    Zadeh, Sahar
    Stewart, A. Keith
    Chen, Christine
    Trudel, Suzanne
    Kukreti, Vishal
    Winter, Andrew
    Franke, Norman
    Reece, Donna E.
    BLOOD, 2009, 114 (22) : 501 - 501
  • [49] Salvage autologous stem cells transplantation and maintenance therapy in relapsed refractory multiple myeloma
    Garrido, David
    Bove, Virginia
    Riva, Eloisa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S145 - S145
  • [50] Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma
    Kauer, Joseph
    Sester, Lilli Sophie
    Kriegsmann, Katharina
    Weinhold, Niels
    Ober, Michael
    Mueller-Tidow, Carsten
    Goldschmidt, Hartmut
    Raab, Marc-Steffen
    Sauer, Sandra
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (03) : 453 - 462
12345